It noted the “discreet platform technology includes a breathable membrane which can be tailored to deliver individual drugs to patients”. Archangels added: “Inhalable medicines are already widely used to treat conditions such as asthma, epilepsy, allergies and Parkinson’s but, to date, delivery options have been limited due to user accessibility, cost, performance and impact on the environment. 1nhaler has developed a way of enabling many different dry powder drugs to be readily delivered in a sustainable, low-cost delivery device.”1nhaler, based in Edinburgh, was founded by Don Smith and Lisa McMyn in 2017. “Securing funding from Archangels is invaluable for the next steps in the 1nhaler’s development. “We’re proud to add 1nhaler to our portfolio of Scotland’s leading life sciences and technology businesses and look forward to working with them to increase the availability of life-saving drugs affordably and sustainably.”

Source: The Herald November 28, 2023 16:21 UTC